CTOs on the Move

Emergent BioSolutions

www.emergentbiosolutions.com

 
Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Matthew Burry
Sr. Director of Information Security Profile
Chii-Ren Tsai
Director, Global Information Security Architecture and Engineering Profile
Eberechi Ugwo-Amole
Director - Information Security and Risk Profile

Jobs

VP, Chief Information Security Officer

Emergent BioSolutions Remote
Details here:
https://careers.emergentbiosolutions.com/job/Gaithersburg-Vice-President%2C-Chief-Information-Security-Officer-Remote-MD-20879/1200080000/?feedId=306800&utm_source=Indeed&utm_campaign=EmergentBio_Indeed&jobPipeline=Indeed

Funding

Emergent BioSolutions raised $20M on 09/25/2019
Emergent BioSolutions raised $14.5M on 04/03/2020

Similar Companies

AngioScore

AngioScore is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zafgen

Zafgen, a biopharmaceutical company, develops obesity therapeutics that help the body regain and sustain a lean and healthy state.

Celmatix

Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sesen Bio

We are passionate in our commitment to improving and renewing people`s lives. Sesen Bio is a late-stage company devWe are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company`s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.eloping fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body`s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium`s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors.